

## Author Acknowledgments

RAPS and lead editor, J. Michael Sprafka, MPH, PhD, thank the following subject matter experts for sharing their experience and knowledge and volunteering their time to contribute to this third edition of *Risk Management Principles for Devices and Pharmaceuticals*.

Nayan Achayara, MBBS,  
MRCP, MFPM  
Chapter 1

Jessica D. Albano, PhD, MPH  
VP, Epidemiology & Analytics  
Syneos Health  
Chapter 14

Krishna Bahadursingh, MD,  
FRCS, MBA, LLB, FFPM  
Head of WorldWide Patient  
Safety-Japan  
Bristol Myers Squibb

Judy Bingham, MHA, GAICD  
Executive Director  
Easington Pty Ltd  
Chapter 4

Mariette Boerstoeel-Streefland,  
MD, MSc, MBA  
Chief Safety Officer, SVP  
Patient Safety  
AstraZeneca  
Chapter 16

Brian Buysse, PhD  
Senior Director, Epidemiology  
Syneos Health  
Chapter 14

Jemma Contreras, PhD  
Advisory Group Lead, R&D  
Consulting  
Syneos Health  
Chapter 23

Lindsay Crampton, BSc  
Advisory Group Lead, Risk  
& Program Management,  
Consulting  
Syneos Health  
Chapter 23

George Cusatis MS, RAC  
Sr. Regulatory Affairs Manager  
Medtronic  
Chapter 3

Karin de Haart, MSc  
Product Strategy Lead  
IQVIA  
Chapter 13

Bruce R. DeMark, PhD  
Retired Research Fellow  
Procter & Gamble  
Pharmaceuticals  
Chapter 20

Debashish Dey, MD, PhD,  
MPH  
Vice President & Head, Drug  
Safety & Pharmacovigilance  
Intellia Therapeutics

Bernadette Dwan, BSc,  
Mpharm, MPSI  
Product Strategy Lead  
IQVIA  
Chapter 13

Michael Engwall, DVM, PhD,  
DSP  
Chapter 6

Sara Ephross, PhD  
Senior Director, Epidemiology  
Syneos Health  
Chapter 14

Matthew Francis, MS, PhD  
Epidemiologist  
Procter and Gamble  
Chapter 10

Angie Graves, MBA,  
MLS(ASCP)  
Senior Director, Business  
Operations, Real World &  
Late Phase  
Syneos Health  
Chapter 14

Mark Heinemann, BSc  
Associate Director, Regulatory  
Advice & Delivery  
Syneos Health France SARL  
Chapter 12

Lisette Hoogendoorn, PhD  
Epidemiology Director  
IQVIA  
Chapter 13

Leo Hovestadt, MSc  
Director Governmental Affairs  
EU

Elekta  
Chapters 7, 11 and 15

Yong Huang, MD, PhD  
Associate Director  
Bristol Myers Squibb Japan  
Chapter 2

Tara Isherwood, MSc, BSc  
(Hons)  
Senior Director, Regulatory  
Advice and Delivery  
Synoes Health  
Chapter 12 and 14

David Konadu, MSc, MASc  
Senior Analyst, Quality  
Systems  
Edwards Lifesciences  
Chapter 5

Richard Loomis, MD  
Chief Informatics Officer,  
Clinical Solutions  
Elsevier  
Chapter 19

Nadja Merkusheva, MD  
Sr. Principal, Strategic RW  
Solutions  
IQVIA  
Chapter 13

Andrej Miotk, PhD  
Senior Product Vigilance  
Manager  
P&G  
Chapter 10

Elaine H. Morrato, DrPH,  
MPH, CPH  
Founding Dean and Professor  
Parkinson School of Health  
Sciences and Public Health  
Loyola University Chicago  
Chapter 21

Hiroshi Nakane  
Senior Manager  
Gilead Sciences  
Chapter 2

Darin Oppenheimer DRSc,  
FRAPS, RAC  
AVP Regulatory Affairs  
Agilent Technologies  
Chapter 3

Debra Porter, MS  
Associate Director, Project  
Management  
Eli Lilly and Company  
Chapter 1

Russ Roberson, PhD, MBA,  
MScME, BScAgE  
Chapter 9

Peter Schiemann, PhD, MBA  
Managing Partner and  
Co-Founder  
Widler & Schiemann Ltd.  
Chapter 8

Paul Sheehan, MSJ, BSc  
Vice President  
Synoes Health  
Chapter 23

Meredith Y. Smith, PhD, MPA,  
FISPE  
Senior Director,  
Implementation Science  
Evidera, Inc., PPD, a part of  
Thermo Fisher Scientific  
Chapter 22

Michael Steinbuch, PhD,  
FISPE  
Senior Director, Global Head  
of Postmarket Product  
Vigilance  
Procter & Gamble  
Chapter 10

Tjeerd-Pieter van Staa, MD,  
MSc, MA, PhD  
Professor of Health eResearch  
University of Manchester  
Chapter 17

Priscilla Velentgas, PhD  
Senior Principal  
IQVIA  
Chapter 13

Angela Walker, MD  
Senior Director of Quality  
Clinical Solutions  
Chapter 19

Beat Widler, PhD, dipl. pharm.  
med.  
Managing Partner and  
Co-Founder  
Widler & Schiemann Ltd.  
Chapter 8

Fei Xue, MD, MSC, ScD  
Global Safety Medical Director,  
Safety Officer  
Amgen Inc.  
Chapter 18

Brande Yaist, MS  
Associate Vice President,  
Value, Evidence and  
Outcomes-Immunology  
Eli Lilly and Company  
Chapter 1